Oct.27,2026
How to Reduce Nonspecific Binders During VHH Biopanning
This guide explains how to reduce nonspecific binders during VHH biopanning through library preparation, target and matrix controls, optimized blocking, negative selection, stringent washing, and clone validation.
View More
Oct.26,2026
How Library Diversity Influences Premade Nanobody Screening Success
Nanobody library diversity determines whether premade screening finds binders across difficult epitopes. This guide covers library selection, panning, NGS, validation, failure fixes, and practical service decisions.
View More
Oct.23,2026
Immunogen QC Checks Before Starting Camelid Immunization
Immunogen QC Checks Before Starting Camelid Immunization explains how purity, identity, aggregation, endotoxin, sterility, and stability testing reduce failed immunizations and support reliable nanobody discovery.
View More
Oct.23,2026
How Epitope Location Influences ADC Nanobody Performance
Epitope location can change ADC nanobody binding, receptor trafficking, internalization, payload release, and therapeutic index. This guide explains how to select, test, and troubleshoot epitope designs with evidence-based controls.
View More
Oct.09,2026
Which Binding Metrics Matter After Yeast Display VHH Screening
Which Binding Metrics Matter After Yeast Display VHH Screening explains how to interpret KD, kon, koff, specificity, avidity, and developability data for reliable VHH candidate selection.
View More
Oct.08,2026
How to Plan Nanobody Discovery from Antigen to Lead Candidate
This guide explains how to plan nanobody discovery from antigen selection to lead candidate, including antigen preparation, immunization or library screening, panning, validation, developability testing, purchasing criteria, and outsourcing risks.
View More
Jun.30,2026
Antibody Humanization: From CDR Grafting to AI-Driven Multi-Objective Optimization
View More
Apr.26,2026
How were single domain antibodies discovered?
Naturally occurring heavy-chain only antibodies (HcAbs) were accidentally discovered in camels by immunologist Raymond Harmers in 1989.
View More
Apr.24,2026
Features of Single Domain Antibodies
VHH, the variable region of a heavy-chain antibody, is the smallest antigen-binding domain with a molecule weight of only 1/10 of conventional antibodies(150-160 kDa), hence the name “nanobody”.
View More
Yeast Display VHH Discovery Service 
Immunogen Design & Production 
Premade Library Screening 
Phage Display Nanobody Discovery Service 
Animal Immunization 
Yeast Display Peptide Library Screening 
Nanobody Discovery for ADC 
Nanobody Discovery for Membrane Targets 
Nanobody Discovery for Cell Therapy 
TCR-Mimic Nanobody Discovery 
Antibody Affinity Maturation Service 
Nanobody Humanization Service 
